lung
cancer
one
top
three
cancer
lead
caus
cancer
mortal
among
men
women
worldwid
case
diagnos
cell
lung
cancer
nsclc
major
patient
nsclc
alreadi
advanc
stage
diagnosi
surgic
treatment
cur
chemotherapi
remain
mainstay
therapi
therefor
novel
chemotherapeut
agent
urgent
need
combin
therapi
improv
cur
effect
reduc
toxic
drug
becom
one
import
mean
improv
surviv
patient
lung
cancer
addit
agent
activ
may
exert
chemoprotect
effect
normal
tissu
toxic
insult
chemotherapi
accumul
evid
verifi
mani
inflammatori
signal
pathway
activ
variou
cancer
therefor
inflamm
play
critic
role
multipl
stage
tumour
develop
includ
initi
promot
invas
metastasi
lung
cancer
associ
inflammatori
environ
mani
inflammatori
mediat
promot
develop
lung
cancer
meanwhil
report
activ
mapk
pathway
play
import
role
initi
develop
inflammatori
process
mapk
signal
cascad
import
regul
cytokin
transmit
signal
sequenti
phosphoryl
event
mapk
phosphoryl
transcript
factor
downstream
kinas
express
mediat
extracellular
stimuli
three
major
subfamili
mapk
kinas
protein
kinas
jnk
sapk
mapk
among
mediat
three
promin
cytokin
tumour
necrosi
factor
alpha
could
contribut
develop
lung
cancer
cytokin
could
induc
transcript
factor
drive
inflamm
includ
one
mani
downstream
target
tnf
receptor
activ
import
ubiquit
transcript
factor
known
regul
express
gene
involv
inflamm
cell
prolifer
migrat
extracellular
matrix
turnov
angiogenesi
berberi
tradit
chines
medicin
berberin
alkaloid
isol
berberi
biolog
pharmacolog
activ
includ
antibacteri
anticanc
activ
wide
use
human
health
care
howev
report
berberin
analogu
dihydroberberin
fig
especi
regard
antitumour
activ
sunitinib
fig
multitarget
receptor
tyrosin
kinas
inhibitor
effect
mani
tyrosin
kinas
includ
pdgfr
vegfr
kit
ret
preclin
clinic
trial
demonstr
sunitinib
potent
antitumour
activ
renal
cell
carcinoma
gastrointestin
stromal
tumour
breast
carcinoma
nsclc
cancer
anticanc
activ
result
dual
inhibitori
effect
toward
angiogenesi
tumour
cell
prolifer
main
advers
reaction
includ
hypodynamia
nausea
thrombocytopenia
attribut
megados
studi
explor
effect
dihydroberberin
lung
cancer
cell
investig
synergist
action
dihydroberberin
sunitinib
lung
carcinoma
cell
vitro
vivo
report
novel
find
dihydroberberin
decreas
effect
dose
increas
sensit
lung
carcinoma
sunitinib
human
lung
cancer
cell
line
purchas
shanghai
institut
cell
biolog
chines
academi
scienc
sh
cellbank
cell
line
frozen
immedi
receipt
sh
cellbank
resuscit
rpmi
media
st
loui
mo
usa
supplement
foetal
bovin
serum
hyclon
logan
utah
usa
use
albc
nude
male
mice
purchas
hunan
sja
laboratori
anim
co
ltd
hunan
pr
china
hous
experiment
anim
center
xian
jiaotong
univers
entir
procedur
carri
accord
approv
guidelin
region
author
accord
china
anim
care
regul
anim
experi
carri
accord
guidelin
approv
institut
anim
care
use
committe
xian
jiaotong
univers
drug
toxic
assay
cell
cellswel
cellswel
cellswel
seed
plate
follow
day
indic
concentr
dihydroberberin
sunitinib
dissolv
media
ad
plate
hr
cell
viabil
assess
use
mtt
assay
absorb
measur
nm
micropl
reader
hercul
ca
usa
determin
combin
index
ci
differ
concentr
dihydroberberin
sunitinib
ad
adher
cell
hr
cell
viabil
calcul
indic
ci
paramet
indic
whether
interact
drug
synergist
addit
antagonist
calcul
use
follow
equat
q
e
ab
e
e
b
e
e
b
e
ab
inhibit
rate
drug
plu
drug
b
e
inhibit
rate
drug
e
b
inhibit
rate
drug
b
exponenti
grow
cell
seed
plate
cellswel
treat
dihydroberberin
sunitinib
dihydroberberin
plu
sunitinib
hr
subsequ
media
chang
cell
cultur
media
addit
day
coloni
obvious
visibl
countabl
coloni
fix
methanol
stain
crystal
violet
imag
photograph
chemiluminesc
fluoresc
imag
system
champchemi
profession
sage
creation
beij
china
invert
fluoresc
microscop
nikon
co
ltd
otawara
tochigi
japan
four
diabet
sever
combin
immunodefici
nodscid
mice
inject
subcutan
right
flank
cell
suspend
steril
physiolog
salin
tumour
measur
callip
everi
day
volum
calcul
use
formula
volum
length
studi
initi
tumour
volum
reach
mice
randomli
assign
four
group
five
micegroup
treat
vehicl
sunitinib
mgkg
daili
dihydroberberin
mgkg
dihydroberberin
plu
sunitinib
mgkg
dihydroberberin
mgkg
sunitinib
everi
day
intragastr
administr
mous
weight
tumour
volum
monitor
everi
day
day
mice
kill
tumour
frozen
western
blot
analysi
fix
paraformaldehyd
immunohistochem
analysi
tumour
specimen
embed
paraffin
cut
section
stain
ihc
sv
histostain
kit
boster
bioengin
co
ltd
wuhan
china
use
ihc
accord
manufactur
instruct
antibodi
use
ihc
dilut
dilut
dilut
dilut
dilut
dilut
dilut
western
blot
protein
extract
lyse
cell
frozen
tissu
nude
mice
ripa
lysi
buffer
contain
proteas
inhibitor
phosphatas
inhibitor
roch
nutley
nj
usa
protein
quantifi
use
bca
assay
pierc
biotechnolog
rockford
illinoi
usa
fifti
microgram
total
protein
per
lane
resolv
use
gel
transfer
polyvinyliden
fluorid
membran
membran
probe
primari
antibodi
follow
incub
horseradish
secondari
antibodi
pierc
biotechnolog
immunoreact
protein
detect
enhanc
chemiluminesc
ecl
plu
reagent
pierc
biotechnolog
gel
run
experiment
condit
gapdh
use
load
control
crop
gel
imag
shown
figur
valu
band
analys
use
imag
pro
plu
softwar
plu
media
cybernet
inc
rockvil
md
usa
target
protein
express
calcul
ratio
grey
scan
valu
protein
extract
frozen
tissu
quantifi
bca
reagent
pierc
biotechnolog
total
protein
use
determin
level
tnf
commerci
avail
elisa
kit
neobiosci
technolog
compani
shenzhen
china
protocol
perform
accord
manufactur
instruct
cell
treat
variou
combin
dihydroberberin
sunitinib
hr
total
rna
extract
trizol
invitrogen
usa
reagent
room
temperatur
store
microarray
experi
perform
whole
human
genom
oligo
microarray
affymetrix
genechip
primeview
human
gene
express
array
santa
clara
ca
usa
contain
human
gene
transcript
entir
procedur
conduct
shanghai
biotechnolog
corpor
china
array
scan
affymetrix
scanner
cat
affymetrix
santa
clara
ca
usa
command
consol
softwar
affymetrix
santa
clara
ca
usa
use
control
scanner
summar
probe
cell
intens
data
cel
file
gener
default
set
raw
data
normal
express
consol
go
annot
gene
twofold
differ
group
determin
statist
signific
p
microarray
data
set
submit
gene
express
omnibu
databas
access
number
exponenti
grow
cell
serum
starv
hr
dihydroberberin
sunitinib
dihydroberberin
plu
sunitinib
hr
cell
harvest
wash
pb
suspend
ethanol
solut
incub
overnight
fixat
cell
wash
thrice
pb
incub
ml
rnase
ml
pi
min
dark
room
temperatur
cell
treat
dihydroberberin
sunitinib
dihydroberberin
plu
sunitinib
hr
harvest
wash
pb
centrifug
cell
suspend
bind
buffer
incub
min
later
pi
ad
incub
dark
room
temperatur
min
stain
cell
analys
fac
becton
dickinson
mountain
view
ca
usa
obtain
data
analys
modfit
lt
softwar
data
express
mean
sem
quantit
experi
statist
analys
differ
group
perform
anova
less
consid
statist
signific
determin
effect
dihydroberberin
sunitinib
nsclc
cell
curv
construct
hr
drug
exposur
growth
cell
significantli
inhibit
manner
vitro
fig
b
valu
dihydroberberin
cell
respect
addit
valu
sunitinib
cell
cell
cell
respect
dihydroberberin
sunitinib
show
less
growth
suppress
cell
cell
order
increas
sensit
cell
dihydroberberin
sunitinib
explor
effect
simultan
treatment
dihydroberberin
combin
sunitinib
dc
determin
synergist
effect
dc
cell
dc
differ
concentr
studi
method
chou
et
al
inhibit
rate
dihydroberberin
combin
sunitinib
differ
concentr
growth
cell
shown
figur
ci
dc
shown
tabl
shown
figur
dihydroberberin
sunitinib
combin
inhibit
rate
respect
cell
meanwhil
ci
valu
dihydroberberin
combin
sunitinib
indic
better
synergist
effect
inhibit
cell
viabil
individu
compound
coloni
format
assay
show
coloni
treat
dc
significantli
fewer
number
smaller
size
control
cell
cell
fig
f
confirm
synergist
effect
dc
evalu
effect
dc
tumour
growth
vivo
xenograft
tumour
model
nude
mice
establish
anticanc
effect
dc
transplant
tumour
shown
figur
tumour
volum
record
everi
day
shown
figur
day
mice
kill
tumour
excis
weigh
fig
result
show
averag
tumour
weight
vehicl
dihydroberberin
sunitinib
treatment
group
g
respect
comparison
tumour
weight
dc
g
therefor
mgkg
dihydroberberin
mgkg
sunitinib
inhibit
xenograft
tumour
growth
respect
combin
dihydroberberin
sunitinib
mark
inhibitori
effect
furthermor
signific
chang
bodi
weight
mice
experi
final
averag
bodi
weight
g
control
dihydroberberin
sunitinib
dc
group
respect
averag
bodi
weight
mice
increas
slightli
differ
statist
signific
stain
fig
show
larg
area
necrosi
mitosi
tissu
control
group
indic
tumour
cell
grown
quickli
caus
necrosi
area
necrosi
group
reduc
compar
control
group
much
signific
inhibit
appear
combin
group
next
effect
dc
tumour
growth
analys
prolifer
index
stain
tumour
biopsi
obtain
group
mice
prolifer
rate
tumour
mice
treat
dc
significantli
lower
compar
mice
treat
vehicl
dihydroberberin
sunitinib
fig
data
show
effect
combin
treatment
superior
effect
dihydroberberin
sunitinib
individu
collect
result
valid
dc
good
synergist
inhibit
tumour
growth
vivo
understand
dc
modul
variou
cell
signal
pathway
effect
dc
signal
cascad
analys
shown
figur
b
c
dc
effect
protein
level
subunit
also
addit
effect
dc
phosphoryl
cell
compar
dihydroberberin
sunitinib
alon
addit
signal
downstream
effector
akt
mtor
show
obviou
chang
cell
tumour
tissu
fig
e
f
clarifi
underli
inhibit
mechan
dc
examin
effect
dc
mapk
cascad
erk
jnk
cell
tumour
tissu
shown
figur
b
c
phosphoryl
jnk
phosphoryl
mapk
total
mapk
protein
decreas
dc
group
compar
singl
agent
cell
tumour
contrast
dc
effect
phosphoryl
erk
cell
tumour
protein
express
jnk
tumour
detect
immunohistochem
stain
fig
provid
vivo
evid
effect
dc
mapk
signal
pathway
consist
western
blot
analysi
result
show
dc
decreas
phosphoryl
jnk
protein
express
xenograft
tumour
fig
data
obvious
indic
dc
modul
jnk
mapk
signal
pathway
possibl
inhibit
prolifer
cell
stain
figur
show
fewer
inflammatori
cell
group
investig
effect
dc
inflamm
measur
protein
express
prostaglandin
e
synthas
cell
tumour
tissu
shown
figur
b
c
dc
inhibit
activ
block
degrad
moreov
dc
markedli
express
protein
effect
inhibit
fig
e
f
meanwhil
immunohistochemistri
result
show
dc
effect
inhibit
protein
express
fig
level
tumour
also
detect
interestingli
demonstr
figur
j
k
dc
effect
inhibit
product
effect
result
indic
dc
diminish
mediat
decreas
express
subsequ
cytokin
product
gain
insight
mechan
dc
synergist
inhibit
use
affymetrix
genechip
primeview
human
gene
express
array
compar
mrna
express
level
untreat
cell
andor
cell
fig
total
differenti
express
gene
gene
identifi
control
cell
p
group
differenti
express
gene
obtain
primari
analysi
analys
go
enrich
pathway
analysi
gene
gene
control
group
shown
figur
microarray
result
indic
larg
number
gene
cell
associ
sever
cancer
biolog
process
cell
cycl
phase
cell
cycl
process
phase
phase
mitot
cell
cycl
homophil
cell
adhes
adhes
fig
upper
panel
shown
lower
panel
figur
main
go
categori
gene
cell
includ
posit
regul
cell
cycl
regul
apoptosi
signal
pathway
neg
regul
apoptosi
among
differenti
express
gene
cell
gene
illustr
figur
corrobor
result
microarray
analys
explor
effect
dc
cell
cycl
express
cell
cycl
protein
close
relat
jnk
mapk
signal
pathway
shown
figur
compar
control
treatment
dc
induc
accumul
cell
phase
cell
cycl
popul
untreat
cell
phase
wherea
cell
treat
dihydroberberin
sunitinib
dc
popul
cell
phase
show
increas
respect
decreas
popul
cell
phase
also
observ
chang
consist
microarray
data
dc
significantli
protein
level
cyclin
cyclin
well
level
cyclin
compar
control
express
cyclin
chang
fig
f
result
indic
dc
would
induc
accumul
cell
phase
cell
cycl
find
suggest
dc
inhibit
cell
viabil
arrest
cell
cycl
phase
modul
jnk
mapk
signal
also
test
effect
dc
cell
apoptosi
shown
figur
fac
result
show
earli
apoptot
cell
lower
right
control
group
treatment
dihydroberberin
sunitinib
dc
percentag
earli
apoptot
cell
respect
chang
late
apoptot
cell
upper
right
data
suggest
dc
could
induc
apoptosi
cell
sunitinib
wide
use
clinic
treatment
sever
human
malign
undesir
sunitinib
use
combin
therapi
result
superior
antitumour
activ
fewer
therefor
necessari
search
novel
agent
enhanc
anticanc
effect
sunitinib
berberin
report
variou
pharmacolog
activ
report
analogu
dihydroberberin
current
studi
evalu
effect
dihydroberberin
lung
cancer
cell
includ
cell
confirm
dihydroberberin
treatment
result
reduct
cell
viabil
manner
meanwhil
found
dihydroberberin
combin
sunitinib
appropri
concentr
dihydroberberin
sunitinib
obviou
synergist
inhibit
cell
viabil
compar
dihydroberberin
sunitinib
alon
furthermor
dihydroberberin
combin
sunitinib
display
good
inhibit
cell
coloni
format
vitro
xenograft
nude
mice
vivo
base
promis
result
explor
molecular
mechan
synerget
interact
dihydroberberin
sunitinib
pathway
play
signific
role
progress
human
lung
cancer
cancer
constitut
activ
compos
catalyt
subunit
regulatori
subunit
catalys
phosphoryl
coordin
cell
growth
cell
migrat
cell
surviv
mapk
signal
pathway
belong
larg
famili
kinas
includ
jnk
form
major
cell
prolifer
signal
pathway
cell
surfac
nucleu
erk
activ
mitogen
stimuli
growth
factor
cytokin
phorbol
ester
involv
regul
cell
prolifer
differenti
meiosi
jnk
famili
member
key
molecul
signal
transduct
variou
kind
stress
well
neural
develop
inflamm
apoptosi
activ
radiat
osmot
pressur
temperatur
other
factor
mediat
growth
inflamm
apoptosi
thu
becom
target
develop
drug
jnk
import
regul
inflammatori
mediat
activ
mapk
pathway
play
essenti
role
initi
develop
inflammatori
process
result
indic
dihydroberberin
combin
sunitinib
effect
variou
isoform
either
catalyt
regulatori
subunit
also
effect
downstream
effector
akt
mtor
interestingli
found
dihydroberberin
combin
sunitinib
inhibit
jnk
activ
cell
tumour
effect
erk
therefor
result
indic
dc
may
good
multitarget
combinatori
drug
mapk
import
member
mapk
famili
control
inflamm
activ
numer
physiolog
chemic
stress
osmot
stress
heat
shock
uv
irradi
ischaemia
inflammatori
stimuli
eg
tnf
factor
mapk
phosphoryl
activ
sever
import
transcript
factor
includ
atf
lead
induct
releas
cytokin
import
signal
pathway
play
vital
role
regul
express
multipl
gene
includ
cytokin
eg
increas
evid
reveal
inhibit
activ
may
lead
allevi
sever
inflammatori
diseas
activ
regul
three
major
step
phosphoryl
degrad
nuclear
transloc
therefor
measur
presenc
indirectli
reflect
activ
transcript
factor
use
western
blot
immunohistochemistri
result
indic
dc
significantli
inhibit
phosphoryl
cell
tumour
previous
report
increas
express
accompani
increas
secret
present
studi
dc
inhibit
level
effect
tumour
elisa
pathway
also
associ
product
import
inflamm
factor
catalys
prostaglandin
synthesi
show
dc
inhibit
express
effect
cell
tumour
base
western
blot
immunohistochemistri
therefor
inhibit
activ
dc
appear
induc
factor
model
system
verifi
mechan
dc
activ
microarray
analysi
use
screen
systemat
differenti
express
gene
control
cell
major
find
microarray
analys
differenti
express
gene
cell
associ
cell
cycl
process
jnk
mapk
signal
pathway
mediat
growth
cell
surviv
tumour
cell
prolifer
close
relat
cell
cycl
cell
cycl
progress
close
relat
variou
cyclin
kinas
cdk
cdk
inhibitor
certain
tumour
suppressor
gene
product
cell
cycl
regul
downstream
jnk
mapk
gene
close
relat
cell
cycl
includ
cyclin
cyclin
cyclin
cyclin
confirm
alter
use
western
blot
meanwhil
data
show
cell
arrest
phase
accompani
declin
level
cyclin
e
increas
level
cyclin
cyclin
flow
cytometri
analysi
result
demonstr
dc
trigger
cell
apoptosi
result
consist
result
signal
pathway
analys
taken
togeth
find
report
work
show
dihydroberberin
increas
sensit
lung
carcinoma
sunitinib
dc
show
inhibit
lung
cancer
cell
growth
vitro
vivo
possibl
jnk
mapk
signal
molecul
simultan
inhibit
phosphoryl
cytokin
inhibit
activ
dc
could
respons
regul
cell
cycl
could
subsequ
lead
jnk
reduc
secret
first
evid
combin
dihydroberberin
sunitinib
could
new
strategi
lung
cancer
treatment
may
becom
potenti
drug
candid
author
declar
conflict
interest
